Abstract
Chronic respiratory infectious diseases are causing high rates of morbidity and mortality worldwide. Tuberculosis, a major cause of chronic pulmonary infection, is currently responsible for approximately 1.5 million deaths per year. Although important advances in the fight against tuberculosis have been made, the progress towards eradication of this disease is being challenged by the dramatic increase in multidrug-resistant bacilli. Nontuberculous mycobacteria causing pulmonary disease and chronic pulmonary aspergillosis are emerging infectious diseases. In contrast to other infectious diseases, chronic respiratory infections share the trait of having highly variable treatment outcomes despite longstanding antimicrobial therapy. Recent scientific progress indicates that medicine is presently at a transition stage from programmatic to personalized management. We explain current state-of-the-art management concepts of chronic pulmonary infectious diseases as well as the underlying methods for therapeutic decisions and their implications for personalized medicine. Furthermore, we describe promising biomarkers and techniques with the potential to serve future individual treatment concepts in this field of difficult-to-treat patients. These include candidate markers to improve individual risk assessment for disease development, the design of tailor-made drug therapy regimens, and individualized biomarker-guided therapy duration to achieve relapse-free cure. In addition, the use of therapeutic drug monitoring to reach optimal drug dosing with the smallest rate of adverse events as well as candidate agents for future host-directed therapies are described. Taken together, personalized medicine will provide opportunities to substantially improve the management and treatment outcome of difficult-to-treat patients with chronic respiratory infections.
References
1.
WHO: Global tuberculosis report 2015, ed 20. Geneva, WHO, 2015, p 115.
2.
Ricketts WM, O'Shaughnessy TC, van Ingen J: Human-to-human transmission of Mycobacterium kansasii or victims of a shared source? Eur Respir J 2014;44:1085-1087.
[PubMed]
3.
Aitken ML, Limaye A, Pottinger P, Whimbey E, Goss CH, Tonelli MR, Cangelosi GA, Dirac MA, Olivier KN, Brown-Elliott BA, McNulty S, Wallace RJ Jr: Respiratory outbreak of Mycobacterium abscessus subspecies massiliense in a lung transplant and cystic fibrosis center. Am J Respir Crit Care Med 2012;185:231-232.
[PubMed]
4.
Bryant JM, Grogono DM, Greaves D, Foweraker J, Roddick I, Inns T, Reacher M, Haworth CS, Curran MD, Harris SR, Peacock SJ, Parkhill J, Floto RA: Whole-genome sequencing to identify transmission of Mycobacterium abscessus between patients with cystic fibrosis: a retrospective cohort study. Lancet 2013;381:1551-1560.
[PubMed]
5.
Henry MT, Inamdar L, O'Riordain D, Schweiger M, Watson JP: Nontuberculous mycobacteria in non-HIV patients: epidemiology, treatment and response. Eur Respir J 2004;23:741-746.
[PubMed]
6.
Andréjak C, Thomsen VØ, Johansen IS, Riis A, Benfield TL, Duhaut P, Sørensen HT, Lescure FX, Thomsen RW: Nontuberculous pulmonary mycobacteriosis in Denmark: incidence and prognostic factors. Am J Respir Crit Care Med 2010;181:514-521.
[PubMed]
7.
Denning DW, Pleuvry A, Cole DC: Global burden of chronic pulmonary aspergillosis as a sequel to pulmonary tuberculosis. Bull World Health Organ 2011;89:864-872.
[PubMed]
8.
Denning DW, Pleuvry A, Cole DC: Global burden of chronic pulmonary aspergillosis complicating sarcoidosis. Eur Respir J 2013;41:621-626.
[PubMed]
9.
Denning DW, Pleuvry A, Cole DC: Global burden of allergic bronchopulmonary aspergillosis with asthma and its complication chronic pulmonary aspergillosis in adults. Med Mycol 2013;51:361-370.
[PubMed]
10.
Ahuja SD, Ashkin D, Avendano M, Banerjee R, Bauer M, Bayona JN, Becerra MC, Benedetti A, Burgos M, Centis R, Chan ED, Chiang CY, Cox H, D'Ambrosio L, DeRiemer K, Dung NH, Enarson D, Falzon D, Flanagan K, Flood J, Garcia-Garcia ML, Gandhi N, Granich RM, Hollm-Delgado MG, Holtz TH, Iseman MD, Jarlsberg LG, Keshavjee S, Kim HR, Koh WJ, Lancaster J, Lange C, de Lange WC, Leimane V, Leung CC, Li J, Menzies D, Migliori GB, Mishustin SP, Mitnick CD, Narita M, O'Riordan P, Pai M, Palmero D, Park SK, Pasvol G, Peña J, Pérez-Guzmán C, Quelapio MI, Ponce-de-Leon A, Riekstina V, Robert J, Royce S, Schaaf HS, Seung KJ, Shah L, Shim TS, Shin SS, Shiraishi Y, Sifuentes-Osornio J, Sotgiu G, Strand MJ, Tabarsi P, Tupasi TE, van Altena R, Van der Walt M, Van der Werf TS, Vargas MH, Viiklepp P, Westenhouse J, Yew WW, Yim JJ; Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB: Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med 2012;9:e1001300.
[PubMed]
11.
Lange C, Abubakar I, Alffenaar JW, Bothamley G, Caminero JA, Carvalho AC, Chang KC, Codecasa L, Correia A, Crudu V, Davies P, Dedicoat M, Drobniewski F, Duarte R, Ehlers C, Erkens C, Goletti D, Günther G, Ibraim E, Kampmann B, Kuksa L, de Lange W, van Leth F, van Lunzen J, Matteelli A, Menzies D, Monedero I, Richter E, Rüsch-Gerdes S, Sandgren A, Scardigli A, Skrahina A, Tortoli E, Volchenkov G, Wagner D, van der Werf MJ, Williams B, Yew WW, Zellweger JP, Cirillo DM; TBNET: Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. Eur Respir J 2014;44:23-63.
[PubMed]
12.
Takeda K, Imamura Y, Takazono T, Yoshida M, Ide S, Hirano K, Tashiro M, Saijo T, Kosai K, Morinaga Y, Nakamura S, Kurihara S, Tsukamoto M, Miyazaki T, Tashiro T, Kohno S, Yanagihara K, Izumikawa K: The risk factors for developing of chronic pulmonary aspergillosis in nontuberculous mycobacteria patients and clinical characteristics and outcomes in chronic pulmonary aspergillosis patients coinfected with nontuberculous mycobacteria. Med Mycol 2016;54:120-127.
[PubMed]
13.
Günther G, Gomez GB, Lange C, Rupert S, van Leth F; TBNET: Availability, price and affordability of anti-tuberculosis drugs in Europe: a TBNET survey. Eur Respir J 2015;45:1081-1088.
[PubMed]
14.
Heyckendorf J, Olaru ID, Ruhwald M, Lange C: Getting personal perspectives on individualized treatment duration in multidrug-resistant and extensively drug-resistant tuberculosis. Am J Respir Crit Care Med 2014;190:374-383.
[PubMed]
15.
Olaru ID, Lange C, Heyckendorf J: Personalized medicine for patients with MDR-TB. J Antimicrob Chemother 2016;71:852-855.
[PubMed]
16.
Streptomycin treatment of tuberculous meningitis. Lancet 1948;1:582-596.
[PubMed]
17.
Fox W, Ellard GA, Mitchison DA: Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis 1999;3(suppl 2):S231-S279.
[PubMed]
18.
WHO: Treatment of tuberculosis: guidelines for national programmes, ed 4. Geneva, WHO, 2010.
19.
Gillespie SH, Billington O: Activity of moxifloxacin against mycobacteria. J Antimicrob Chemother 1999;44:393-395.
[PubMed]
20.
Gillespie SH, Crook AM, McHugh TD, Mendel CM, Meredith SK, Murray SR, Pappas F, Phillips PP, Nunn AJ; REMoxTB Consortium: Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med 2014;371:1577-1587.
[PubMed]
21.
Jindani A, Harrison TS, Nunn AJ, Phillips PP, Churchyard GJ, Charalambous S, Hatherill M, Geldenhuys H, McIlleron HM, Zvada SP, Mungofa S, Shah NA, Zizhou S, Magweta L, Shepherd J, Nyirenda S, van Dijk JH, Clouting HE, Coleman D, Bateson AL, McHugh TD, Butcher PD, Mitchison DA; RIFAQUIN Trial Team: High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med 2014;371:1599-1608.
[PubMed]
22.
Merle CS, Fielding K, Sow OB, Gninafon M, Lo MB, Mthiyane T, Odhiambo J, Amukoye E, Bah B, Kassa F, N'Diaye A, Rustomjee R, de Jong BC, Horton J, Perronne C, Sismanidis C, Lapujade O, Olliaro PL, Lienhardt C; OFLOTUB/Gatifloxacin for Tuberculosis Project: A four-month gatifloxacin-containing regimen for treating tuberculosis. N Engl J Med 2014;371:1588-1598.
[PubMed]
23.
Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, Zeller K, Andrews J, Friedland G: Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006;368:1575-1580.
[PubMed]
24.
WHO: Guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Geneva, WHO, 2011.
25.
Van Deun A, Maug AK, Salim MA, Das PK, Sarker MR, Daru P, Rieder HL: Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010;182:684-692.
[PubMed]
26.
WHO: WHO treatment guidelines for drug-resistant tuberculosis: 2016 update. Geneva, WHO, 2016.
27.
WHO: The use of delamanid in the treatment of multidrug-resistant tuberculosis. Interim policy guidance. Geneva, WHO, 2015.
28.
WHO: The use of bedaquiline in the treatment of multidrug-resistant tuberculosis. Interim policy guidance. Geneva, WHO, 2013.
29.
Davies Forsman L, Giske CG, Bruchfeld J, Schön T, Juréen P, Ängeby K: Meropenem-clavulanate has high in vitro activity against multidrug-resistant Mycobacterium tuberculosis. Int J Mycobacteriol 2015;4(suppl 1): 80-81.
[PubMed]
30.
Hugonnet JE, Tremblay LW, Boshoff HI, Barry CE 3rd, Blanchard JS: Meropenem-clavulanate is effective against extensively drug- resistant Mycobacterium tuberculosis. Science 2009;323:1215-1218.
[PubMed]
31.
Falkinham JO 3rd: Environmental sources of nontuberculous mycobacteria. Clin Chest Med 2015;36:35-41.
[PubMed]
32.
Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, Holland SM, Horsburgh R, Huitt G, Iademarco MF, Iseman M, Olivier K, Ruoss S, von Reyn CF, Wallace RJ Jr, Winthrop K: An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007;175:367-416.
[PubMed]
33.
Wolinsky E: When is an infection disease? Rev Infect Dis 1981;3:1025-1027.
[PubMed]
34.
Wassilew N, Hoffmann H, Andréjak C, Lange C: Pulmonary disease caused by non-tuberculous mycobacteria. Respiration 2016;91:386-402.
[PubMed]
35.
Egelund EF, Fennelly KP, Peloquin CA: Medications and monitoring in nontuberculous mycobacteria infections. Clin Chest Med 2015;36:55-66.
[PubMed]
36.
Kasperbauer SH, De Groote MA: The treatment of rapidly growing mycobacterial infections. Clin Chest Med 2015;36:67-78.
[PubMed]
37.
van Ingen J, Kuijper EJ: Drug susceptibility testing of nontuberculous mycobacteria. Future Microbiol 2014;9:1095-1110.
[PubMed]
38.
CLSI: M24-A2: Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes; Approved Standard, ed 2. Wayne, CLSI, 2011.
39.
Nessar R, Cambau E, Reyrat JM, Murray A, Gicquel B: Mycobacterium abscessus: a new antibiotic nightmare. J Antimicrob Chemother 2012;67:810-818.
[PubMed]
40.
Horsburgh CR Jr, Mason UG 3rd, Heifets LB, Southwick K, Labrecque J, Iseman MD: Response to therapy of pulmonary Mycobacterium avium-intracellulare infection correlates with results of in vitro susceptibility testing. Am Rev Respir Dis 1987;135:418-421.
[PubMed]
41.
Wallace RJ Jr, Brown BA, Griffith DE, Girard WM, Murphy DT: Clarithromycin regimens for pulmonary Mycobacterium avium complex. The first 50 patients. Am J Respir Crit Care Med 1996;153:1766-1772.
[PubMed]
42.
van Ingen J, Ferro BE, Hoefsloot W, Boeree MJ, van Soolingen D: Drug treatment of pulmonary nontuberculous mycobacterial disease in HIV-negative patients: the evidence. Expert Rev of Anti Infect Ther 2013;11:1065-1077.
[PubMed]
43.
Kobashi Y, Matsushima T, Oka M: A double-blind randomized study of aminoglycoside infusion with combined therapy for pulmonary Mycobacterium avium complex disease. Respir Med 2007;101:130-138.
[PubMed]
44.
van Ingen J, Verhagen AF, Dekhuijzen PN, van Soolingen D, Magis-Escurra C, Boeree MJ, de Lange WC: Surgical treatment of non-tuberculous mycobacterial lung disease: strike in time. Int J Tuberc Lung Dis 2010;14:99-105.
[PubMed]
45.
Kang HK, Park HY, Kim D, Jeong BH, Jeon K, Cho JH, Kim HK, Choi YS, Kim J, Koh WJ: Treatment outcomes of adjuvant resectional surgery for nontuberculous mycobacterial lung disease. BMC Infect Dis 2015;15:76.
[PubMed]
46.
van Ingen J: Treatment of pulmonary disease caused by non-tuberculous mycobacteria. Lancet Respir Med 2015;3:179-180.
[PubMed]
47.
Wassilew N, Lange C: Cure not possible, by definition. Am J Respir Crit Care Med 2015;192:1255-1256.
[PubMed]
48.
Wallace RJ Jr, Brown-Elliott BA, McNulty S, Philley JV, Killingley J, Wilson RW, York DS, Shepherd S, Griffith DE: Macrolide/azalide therapy for nodular/bronchiectatic Mycobacterium avium complex lung disease. Chest 2014;146:276-282.
[PubMed]
49.
Denning DW, Cadranel J, Beigelman-Aubry C, Ader F, Chakrabarti A, Blot S, Ullmann AJ, Dimopoulos G, Lange C; European Society for Clinical Microbiology and Infectious Diseases and European Respiratory Society: Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management. Eur Respir J 2016;47:45-68.
[PubMed]
50.
Denning DW, Riniotis K, Dobrashian R, Sambatakou H: Chronic cavitary and fibrosing pulmonary and pleural aspergillosis: case series, proposed nomenclature change, and review. Clin Infect Dis 2003;37(suppl 3):S265-S280.
[PubMed]
51.
Kosmidis C, Denning DW: The clinical spectrum of pulmonary aspergillosis. Thorax 2015;70:270-277.
[PubMed]
52.
Franquet T, Müller NL, Giménez A, Guembe P, de La Torre J, Bagué S: Spectrum of pulmonary aspergillosis: histologic, clinical, and radiologic findings. Radiographics 2001;21:825-837.
[PubMed]
53.
Yoon SH, Park CM, Goo JM, Lee HJ: Pulmonary aspergillosis in immunocompetent patients without air-meniscus sign and underlying lung disease: CT findings and histopathologic features. Acta Radiol 2011;52:756-761.
[PubMed]
54.
Roberts CM, Citron KM, Strickland B: Intrathoracic aspergilloma: role of CT in diagnosis and treatment. Radiology 1987;165:123-128.
[PubMed]
55.
Soubani AO, Chandrasekar PH: The clinical spectrum of pulmonary aspergillosis. Chest 2002;121:1988-1999.
[PubMed]
56.
Dai Z, Zhao H, Cai S, Lv Y, Tong W: Invasive pulmonary aspergillosis in non-neutropenic patients with and without underlying disease: a single-centre retrospective analysis of 52 subjects. Respirology 2013;18:323-331.
[PubMed]
57.
Uffredi ML, Mangiapan G, Cadranel J, Kac G: Significance of Aspergillus fumigatus isolation from respiratory specimens of nongranulocytopenic patients. Eur J Clin Microbiol Infect Dis 2003;22:457-462.
[PubMed]
58.
Page ID, Richardson MD, Denning DW: Comparison of six Aspergillus-specific IgG assays for the diagnosis of chronic pulmonary aspergillosis (CPA). J Infect 2016;72:240-249.
[PubMed]
59.
Mearns M, Longbottom J, Batten J: Precipitating antibodies to Aspergillus fumigatus in cystic fibrosis. Lancet 1967;1:538-539.
[PubMed]
60.
Baxter CG, Denning DW, Jones AM, Todd A, Moore CB, Richardson MD: Performance of two Aspergillus IgG EIA assays compared with the precipitin test in chronic and allergic aspergillosis. Clin Microbiol Infect 2013;19:E197-E204.
[PubMed]
61.
Longbottom JL, Austwick PK: Antigens and allergens of Aspergillus fumigatus. I. Characterization by quantitative immunoelectrophoretic techniques. J Allergy Clin Immunol 1986;78(pt 1):9-17.
[PubMed]
62.
Farid S, Mohamed S, Devbhandari M, Kneale M, Richardson M, Soon SY, Jones MT, Krysiak P, Shah R, Denning DW, Rammohan K: Results of surgery for chronic pulmonary aspergillosis, optimal antifungal therapy and proposed high risk factors for recurrence - a National Centre's experience. J Cardiothorac Surg 2013;8:180.
[PubMed]
63.
Osaki S, Nakanishi Y, Wataya H, Takayama K, Inoue K, Takaki Y, Murayama S, Hara N: Prognosis of bronchial artery embolization in the management of hemoptysis. Respiration 2000;67:412-416.
[PubMed]
64.
Kravitz JN, Berry MW, Schabel SI, Judson MA: A modern series of percutaneous intracavitary instillation of amphotericin B for the treatment of severe hemoptysis from pulmonary aspergilloma. Chest 2013;143:1414-1421.
[PubMed]
65.
Kohno S, Masaoka T, Yamaguchi H, Mori T, Urabe A, Ito A, Niki Y, Ikemoto H: A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan. Scand J Infect Dis 2004;36:372-379.
[PubMed]
66.
Boehme CC, Nicol MP, Nabeta P, Michael JS, Gotuzzo E, Tahirli R, Gler MT, Blakemore R, Worodria W, Gray C, Huang L, Caceres T, Mehdiyev R, Raymond L, Whitelaw A, Sagadevan K, Alexander H, Albert H, Cobelens F, Cox H, Alland D, Perkins MD: Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 2011;377:1495-1505.
[PubMed]
67.
Arendrup MC, Cuenca-Estrella M, Lass-Flörl C, Hope WW: Breakpoints for antifungal agents: an update from EUCAST focussing on echinocandins against Candida spp. and triazoles against Aspergillus spp. Drug Resist Updat 2013;16:81-95.
[PubMed]
68.
Mack U, Migliori GB, Sester M, Rieder HL, Ehlers S, Goletti D, Bossink A, Magdorf K, Hölscher C, Kampmann B, Arend SM, Detjen A, Bothamley G, Zellweger JP, Milburn H, Diel R, Ravn P, Cobelens F, Cardona PJ, Kan B, Solovic I, Duarte R, Cirillo DM, Lange C; TBNET: LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement. Eur Respir J 2009;33:956-973.
[PubMed]
69.
Sester M, van Leth F, Bruchfeld J, Bumbacea D, Cirillo DM, Dilektasli AG, Domínguez J, Duarte R, Ernst M, Eyuboglu FO, Gerogianni I, Girardi E, Goletti D, Janssens JP, Julander I, Lange B, Latorre I, Losi M, Markova R, Matteelli A, Milburn H, Ravn P, Scholman T, Soccal PM, Straub M, Wagner D, Wolf T, Yalcin A, Lange C; TBNET: Risk assessment of tuberculosis in immunocompromised patients. A TBNET study. Am J Respir Crit Care Med 2014;190:1168-1176.
[PubMed]
70.
Zellweger JP, Sotgiu G, Block M, Dore S, Altet N, Blunschi R, Bogyi M, Bothamley G, Bothe C, Codecasa L, Costa P, Domínguez J, Duarte R, Fløe A, Fresard I, García-García JM, Goletti D, Halm P, Hellwig D, Henninger E, Heykes-Uden H, Horn L, Kruczak K, Latorre I, Pache G, Rath H, Ringshausen FC, Ruiz AS, Solovic I, Souza-Galvão ML, Widmer U, Witte P, Lange C; TBNET: Risk assessment of tuberculosis in contacts by IFN-γ release assays. A Tuberculosis Network European Trials Group Study. Am J Respir Crit Care Med 2015;191:1176-1184.
[PubMed]
71.
Sester M, van Crevel R, Leth F, Lange C: Numbers needed to treat to prevent tuberculosis. Eur Respir J 2015;46:1836-1838.
[PubMed]
72.
Gutsfeld C, Olaru ID, Vollrath O, Lange C: Attitudes about tuberculosis prevention in the elimination phase: a survey among physicians in Germany. PLoS One 2014;9:e112681.
[PubMed]
73.
Zak DE, Penn-Nicholson A, Scriba TJ, Thompson E, Suliman S, Amon LM, Mahomed H, Erasmus M, Whatney W, Hussey GD, Abrahams D, Kafaar F, Hawkridge T, Verver S, Hughes EJ, Ota M, Sutherland J, Howe R, Dockrell HM, Boom WH, Thiel B, Ottenhoff THM, Mayanja-Kizza H, Crampin AC, Downing K, Hatherill M, Valvo J, Shankar S, Parida SK, Kaufmann SHE, Walzl G, Aderem A, Hanekom WA: A blood RNA signature for tuberculosis disease risk: a prospective cohort study. Lancet 2016;387:2312-2322.
[PubMed]
74.
Rothenberg ME: Eosinophilia. N Engl J Med 1998;338:1592-1600.
[PubMed]
75.
Meng Y, Lichtman AH, Bridgen DT, Martin BR: Inhalation studies with drugs of abuse. NIDA Res Monogr 1997;173:201-224.
[PubMed]
76.
Brigden ML: The monitoring of potential long-term comlications [sic!] in treated adult cancer patients. Ann Saudi Med 1997;17:622-628.
[PubMed]
77.
Brigden M, Graydon C: Eosinophilia detected by automated blood cell counting in ambulatory North American outpatients. Incidence and clinical significance. Arch Pathol Lab Med 1997;121:963-967.
[PubMed]
78.
Domínguez J, Boettger EC, Cirillo D, Cobelens F, Eisenach KD, Gagneux S, Hillemann D, Horsburgh R, Molina-Moya B, Niemann S, Tortoli E, Whitelaw A, Lange C; TBNET; RESIST-TB Networks: Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a TBNET/RESIST-TB consensus statement. Int J Tuberc Lung Dis 2016;20:24-42.
[PubMed]
79.
Walker TM, Kohl TA, Omar SV, Hedge J, Del Ojo Elias C, Bradley P, Iqbal Z, Feuerriegel S, Niehaus KE, Wilson DJ, Clifton DA, Kapatai G, Ip CL, Bowden R, Drobniewski FA, Allix-Béguec C, Gaudin C, Parkhill J, Diel R, Supply P, Crook DW, Smith EG, Walker AS, Ismail N, Niemann S, Peto TE; Modernizing Medical Microbiology (MMM) Informatics Group: Whole-genome sequencing for prediction of Mycobacterium tuberculosis drug susceptibility and resistance: a retrospective cohort study. Lancet Infect Dis 2015;15:1193-1202.
[PubMed]
80.
Pankhurst LJ, Del Ojo Elias C, Votintseva AA, Walker TM, Cole K, Davies J, Fermont JM, Gascoyne-Binzi DM, Kohl TA, Kong C, Lemaitre N, Niemann S, Paul J, Rogers TR, Roycroft E, Smith EG, Supply P, Tang P, Wilcox MH, Wordsworth S, Wyllie D, Xu L, Crook DW; COMPASS-TB Study Group: Rapid, comprehensive, and affordable mycobacterial diagnosis with whole-genome sequencing: a prospective study. Lancet Respir Med 2016;4:49-58.
[PubMed]
81.
Brown AC, Bryant JM, Einer-Jensen K, Holdstock J, Houniet DT, Chan JZ, Depledge DP, Nikolayevskyy V, Broda A, Stone MJ, Christiansen MT, Williams R, McAndrew MB, Tutill H, Brown J, Melzer M, Rosmarin C, McHugh TD, Shorten RJ, Drobniewski F, Speight G, Breuer J: Rapid whole-genome sequencing of Mycobacterium tuberculosis isolates directly from clinical samples. J Clin Microbiol 2015;53:2230-2237.
[PubMed]
82.
Stucki D, Ballif M, Bodmer T, Coscolla M, Maurer AM, Droz S, Butz C, Borrell S, Längle C, Feldmann J, Furrer H, Mordasini C, Helbling P, Rieder HL, Egger M, Gagneux S, Fenner L: Tracking a tuberculosis outbreak over 21 years: strain-specific single-nucleotide polymorphism typing combined with targeted whole-genome sequencing. J Infect Dis 2015;211:1306-1316.
[PubMed]
83.
Hasnain SE, O'Toole RF, Grover S, Ehtesham NZ: Whole genome sequencing: a new paradigm in the surveillance and control of human tuberculosis. Tuberculosis (Edinb) 2015;95:91-94.
[PubMed]
84.
Alsultan A, Peloquin CA: Therapeutic drug monitoring in the treatment of tuberculosis: an update. Drugs 2014;74:839-854.
[PubMed]
85.
Srivastava S, Pasipanodya JG, Meek C, Leff R, Gumbo T: Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability. J Infect Dis 2011;204:1951-1959.
[PubMed]
86.
Gumbo T, Angulo-Barturen I, Ferrer-Bazaga S: Pharmacokinetic-pharmacodynamic and dose-response relationships of antituberculosis drugs: recommendations and standards for industry and academia. J Infect Dis 2015;211(suppl 3):S96-S106.
[PubMed]
87.
Zuur MA, Bolhuis MS, Anthony R, den Hertog A, van der Laan T, Wilffert B, de Lange W, van Soolingen D, Alffenaar JC: Current status and opportunities for therapeutic drug monitoring in the treatment of tuberculosis. Expert Opin Drug Metab Toxicol 2016;12:509-521.
[PubMed]
88.
Alffenaar JW, Bolhuis M, van Hateren K, Sturkenboom M, Akkerman O, de Lange W, Greijdanus B, van der Werf T, Touw D: Determination of bedaquiline in human serum using liquid chromatography-tandem mass spectrometry. Antimicrob Agents Chemother 2015;59:5675-5680.
[PubMed]
89.
Han M, Jun SH, Lee JH, Park KU, Song J, Song SH: Method for simultaneous analysis of nine second-line anti-tuberculosis drugs using UPLC-MS/MS. J Antimicrob Chemother 2013;68:2066-2073.
[PubMed]
90.
Chideya S, Winston CA, Peloquin CA, Bradford WZ, Hopewell PC, Wells CD, Reingold AL, Kenyon TA, Moeti TL, Tappero JW: Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana. Clin Infect Dis 2009;48:1685-1694.
[PubMed]
91.
Pasipanodya JG, McIlleron H, Burger A, Wash PA, Smith P, Gumbo T: Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J Infect Dis 2013;208:1464-1473.
[PubMed]
92.
Weiner M, Benator D, Burman W, Peloquin CA, Khan A, Vernon A, Jones B, Silva-Trigo C, Zhao Z, Hodge T: Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. Clin Infect Dis 2005;40:1481-1491.
[PubMed]
93.
Bloom CI, Graham CM, Berry MP, Wilkinson KA, Oni T, Rozakeas F, Xu Z, Rossello-Urgell J, Chaussabel D, Banchereau J, Pascual V, Lipman M, Wilkinson RJ, O'Garra A: Detectable changes in the blood transcriptome are present after two weeks of antituberculosis therapy. PLoS One 2012;7:e46191.
[PubMed]
94.
Berry MP, Graham CM, McNab FW, Xu Z, Bloch SA, Oni T, et al: An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 2010;466:973-977.
[PubMed]
95.
McNab FW, Berry MPR, Graham CM, Bloch SA, Oni T, Wilkinson KA, Wilkinson RJ, Kon OM, Banchereau J, Chaussabel D, O'Garra A: Programmed death ligand 1 is over-expressed by neutrophils in the blood of patients with active tuberculosis. Eur J Immunol 2011;41:1941-1947.
[PubMed]
96.
Riou C, Perez Peixoto B, Roberts L, Ronacher K, Walzl G, Manca C, Rustomjee R, Mthiyane T, Fallows D, Gray CM, Kaplan G: Effect of standard tuberculosis treatment on plasma cytokine levels in patients with active pulmonary tuberculosis. PLoS One 2012;7:e36886.
[PubMed]
97.
Wu YE, Peng WG, Cai YM, Zheng GZ, Zheng GL, Lin JH, Zhang SW, Li K: Decrease in CD4+CD25+FoxP3+ Treg cells after pulmonary resection in the treatment of cavity multidrug-resistant tuberculosis. Int J Infect Dis 2010;14:e815-e822.
[PubMed]
98.
Singh A, Mohan A, Dey AB, Mitra DK: Inhibiting the programmed death 1 pathway rescues Mycobacterium tuberculosis-specific interferon γ-producing T cells from apoptosis in patients with pulmonary tuberculosis. J Infect Dis 2013;208:603-615.
[PubMed]
99.
Ralph AP, Ardian M, Wiguna A, Maguire GP, Becker NG, Drogumuller G, Wilks MJ, Waramori G, Tjitra E, Sandjaja, Kenagalem E, Pontororing GJ, Anstey NM, Kelly PM: A simple, valid, numerical score for grading chest X-ray severity in adult smear-positive pulmonary tuberculosis. Thorax 2010;65:863-869.
[PubMed]
100.
Wejse C, Gustafson P, Nielsen J, Gomes VF, Aaby P, Andersen PL, Sodemann M: TBscore: signs and symptoms from tuberculosis patients in a low-resource setting have predictive value and may be used to assess clinical course. Scand J Infect Dis 2008;40:111-120.
[PubMed]
101.
Kitada S, Levin A, Hiserote M, Harbeck RJ, Czaja CA, Huitt G, Kasperbauer SH, Daley CL: Serodiagnosis of Mycobacterium avium complex pulmonary disease in the USA. Eur Respir J 2013;42:454-460.
[PubMed]
102.
Kitada S, Maekura R, Toyoshima N, Naka T, Fujiwara N, Kobayashi M, Yano I, Ito M, Kobayashi K: Use of glycopeptidolipid core antigen for serodiagnosis of Mycobacterium avium complex pulmonary disease in immunocompetent patients. Clin Diagn Lab Immunol 2005;12:44-51.
[PubMed]
103.
Jeong BH, Kim SY, Jeon K, Lee SY, Shin SJ, Koh WJ: Serodiagnosis of Mycobacterium avium complex and Mycobacterium abscessus complex pulmonary disease by use of IgA antibodies to glycopeptidolipid core antigen. J Clin Microbiol 2013;51:2747-2749.
[PubMed]
104.
Ferro BE, van Ingen J, Wattenberg M, van Soolingen D, Mouton JW: Time-kill kinetics of antibiotics active against rapidly growing mycobacteria. J Antimicrob Chemother 2015;70:811-817.
[PubMed]
105.
Ferro BE, van Ingen J, Wattenberg M, van Soolingen D, Mouton JW: Time-kill kinetics of slowly growing mycobacteria common in pulmonary disease. J Antimicrob Chemother 2015;70:2838-2843.
[PubMed]
106.
van Ingen J, Egelund EF, Levin A, Totten SE, Boeree MJ, Mouton JW, Aarnoutse RE, Heifets LB, Peloquin CA, Daley CL: The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment. Am J Respir Crit Care Med 2012;186:559-565.
[PubMed]
107.
van Ingen J, Totten SE, Heifets LB, Boeree MJ, Daley CL: Drug susceptibility testing and pharmacokinetics question current treatment regimens in Mycobacterium simiae complex disease. Int J Antimicrob Agents 2012;39:173-176.
[PubMed]
108.
Brown-Elliott BA, Crist CJ, Mann LB, Wilson RW, Wallace RJ Jr: In vitro activity of linezolid against slowly growing nontuberculous mycobacteria. Antimicrob Agents Chemother 2003;47:1736-1738.
[PubMed]
109.
Olivier KN, Gupta R, Daley CL, Winthrop KL, Ruoss S, Addrizzo-Harris DJ, Flume P, Dorgan D, Salathe MA, Brown-Elliott BA, Wallace RJ, Griffith DE: A randomized, double-blind, placebo-controlled study of liposomal amikacin for inhalation (Arikace®) in patients with recalcitrant nontuberculous mycobacterial lung disease. Am J Respir Crit Care Med 2014;189:A4126.
110.
Philley JV, Wallace RJ Jr, Benwill JL, Taskar V, Brown-Elliott BA, Thakkar F, Aksamit TR, Griffith DE: Preliminary results of bedaquiline as salvage therapy for patients with nontuberculous mycobacterial lung disease. Chest 2015;148:499-506.
[PubMed]
111.
Park WB, Kim NH, Kim KH, Lee SH, Nam WS, Yoon SH, Song KH, Choe PG, Kim NJ, Jang IJ, Oh MD, Yu KS: The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial. Clin Infect Dis 2012;55:1080-1087.
[PubMed]
112.
Kim SH, Yim DS, Choi SM, Kwon JC, Han S, Lee DG, Park C, Kwon EY, Park SH, Choi JH, Yoo JH: Voriconazole-related severe adverse events: clinical application of therapeutic drug monitoring in Korean patients. Int J Infect Dis 2011;15:e753-e758.
[PubMed]
113.
Kaufmann SH, Lange C, Rao M, Balaji KN, Lotze M, Schito M, Zumla AI, Maeurer M: Progress in tuberculosis vaccine development and host-directed therapies - a state of the art review. Lancet Respir Med 2014;2:301-320.
[PubMed]
114.
O'Connor G, Gleeson LE, Fagan-Murphy A, Cryan SA, O'Sullivan MP, Keane J: Sharpening nature's tools for efficient tuberculosis control: a review of the potential role and development of host-directed therapies and strategies for targeted respiratory delivery. Adv Drug Deliv Rev 2016;102:33-54.
[PubMed]
115.
Wiid I, Hoal-van Helden E, Hon D, Lombard C, van Helden P: Potentiation of isoniazid activity against Mycobacterium tuberculosis by melatonin. Antimicrob Agents Chemother 1999;43:975-977.
[PubMed]
116.
Critchley JA, Young F, Orton L, Garner P: Corticosteroids for prevention of mortality in people with tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 2013;13:223-237.
[PubMed]
117.
Volchegorskiĭ IA, Novoselov PN, Astakhova TV: Effect of ascorbic acid and emoxypin on the efficiency of complex chemotherapy for infiltrative pulmonary tuberculosis (in Russian). Ter Arkh 2009;81:21-24.
[PubMed]
118.
Martineau AR, Timms PM, Bothamley GH, Hanifa Y, Islam K, Claxton AP, Packe GE, Moore-Gillon JC, Darmalingam M, Davidson RN, Milburn HJ, Baker LV, Barker RD, Woodward NJ, Venton TR, Barnes KE, Mullett CJ, Coussens AK, Rutterford CM, Mein CA, Davies GR, Wilkinson RJ, Nikolayevskyy V, Drobniewski FA, Eldridge SM, Griffiths CJ: High-dose vitamin D3 during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised controlled trial. Lancet 2011;377:242-250.
[PubMed]
119.
Vilaplana C, Marzo E, Tapia G, Diaz J, Garcia V, Cardona PJ: Ibuprofen therapy resulted in significantly decreased tissue bacillary loads and increased survival in a new murine experimental model of active tuberculosis. J Infect Dis 2013;208:199-202.
[PubMed]
120.
Maiga M, Ammerman NC, Maiga MC, Tounkara A, Siddiqui S, Polis M, Murphy R, Bishai WR: Adjuvant host-directed therapy with types 3 and 5 but not type 4 phosphodiesterase inhibitors shortens the duration of tuberculosis treatment. J Infect Dis 2013;208:512-519.
[PubMed]
121.
Gupta S, Tyagi S, Almeida DV, Maiga MC, Ammerman NC, Bishai WR: Acceleration of tuberculosis treatment by adjunctive therapy with verapamil as an efflux inhibitor. Am J Respir Crit Care Med 2013;188:600-607.
[PubMed]
122.
Shaw SY, Tran K, Castoreno AB, Peloquin JM, Lassen KG, Khor B, Aldrich LN, Tan PH, Graham DB, Kuballa P, Goel G, Daly MJ, Shamji AF, Schreiber SL, Xavier RJ: Selective modulation of autophagy, innate immunity, and adaptive immunity by small molecules. ACS Chem Biol 2013;8:2724-2733.
[PubMed]
123.
Zumla A, Maeurer M, Moll G, Mayosi BM: Host-directed therapies for tuberculous pericarditis. Int J Infect Dis 2015;32:30-31.
[PubMed]
124.
Skrahin A, Ahmed RK, Ferrara G, Rane L, Poiret T, Isaikina Y, Skrahina A, Zumla A, Maeurer MJ: Autologous mesenchymal stromal cell infusion as adjunct treatment in patients with multidrug and extensively drug-resistant tuberculosis: an open-label phase 1 safety trial. Lancet Respir Med 2014;2:108-122.
[PubMed]
125.
Gao XF, Yang ZW, Li J: Adjunctive therapy with interferon-γ for the treatment of pulmonary tuberculosis: a systematic review. Int J Infect Dis 2011;15:e594-e600.
[PubMed]
126.
Greinert U, Ernst M, Schlaak M, Entzian P: Interleukin-12 as successful adjuvant in tuberculosis treatment. Eur Respir J 2001;17:1049-1051.
[PubMed]
127.
Marais BJ, Lönnroth K, Lawn SD, Migliori GB, Mwaba P, Glaziou P, Bates M, Colagiuri R, Zijenah L, Swaminathan S, Memish ZA, Pletschette M, Hoelscher M, Abubakar I, Hasan R, Zafar A, Pantaleo G, Craig G, Kim P, Maeurer M, Schito M, Zumla A: Tuberculosis comorbidity with communicable and non-communicable diseases: integrating health services and control efforts. Lancet Infect Dis 2013;13:436-448.
[PubMed]
128.
Moore C, Wisnivesky J, Williams S, McGinn T: Medical errors related to discontinuity of care from an inpatient to an outpatient setting. J Gen Intern Med 2003;18:646-651.
[PubMed]
129.
Craig GM, Booth H, Hall J, Story A, Hayward A, Goodburn A, Zumla A: Establishing a new service role in tuberculosis care: the tuberculosis link worker. J Adv Nurs 2008;61:413-424.
[PubMed]
130.
van Hest NA, Aldridge RW, de Vries G, Sandgren A, Hauer B, Hayward A, Arrazola de Oñate W, Haas W, Codecasa LR, Caylà JA, Story A, Antoine D, Gori A, Quabeck L, Jonsson J, Wanlin M, Orcau Å, Rodes A, Dedicoat M, Antoun F, van Deutekom H, Keizer S, Abubakar I: Tuberculosis control in big cities and urban risk groups in the European Union: a consensus statement. Euro Surveill 2014;19:20728.
[PubMed]
131.
Lass-Flörl C: Susceptibility testing in Aspergillus species complex. Clin Microbiol Infect 2014;20(suppl 6):49-53.
[PubMed]
132.
Kumaresan PR, Manuri PR, Albert ND, Maiti S, Singh H, Mi T, Roszik J, Rabinovich B, Olivares S, Krishnamurthy J, Zhang L, Najjar AM, Huls MH, Lee DA, Champlin RE, Kontoyiannis DP, Cooper LJ: Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection. Proc Natl Acad Sci USA 2014;111:10660-10665.
[PubMed]
133.
Dotis J, Panagopoulou P, Filioti J, Winn R, Toptsis C, Panteliadis C, Roilides E: Femoral osteomyelitis due to Aspergillus nidulans in a patient with chronic granulomatous disease. Infection 2003;31:121-124.
[PubMed]
134.
Trojan T, Collins R, Khan DA: Safety and efficacy of treatment using interleukin-2 in a patient with idiopathic CD4+ lymphopenia and Mycobacterium avium-intracellulare. Clin Exp Immunol 2009;156:440-445.
[PubMed]
135.
Remiszewski P, Roszkowska-Sliz B, Winek J, Chapgier A, Feinberg J, Langfort R, Bestry I, Augustynowicz-Kopeć E, Ptak J, Casanova JL, Rowińska-Zakrzewska E: Disseminated Mycobacterium avium infection in a 20-year-old female with partial recessive IFNγR1 deficiency. Respiration 2006;73:375-378.
[PubMed]
136.
Giosuè S, Casarini M, Ameglio F, Zangrilli P, Palla M, Altieri AM, Bisetti A: Aerosolized interferon-α treatment in patients with multi-drug-resistant pulmonary tuberculosis. Eur Cytokine Netw 2000;11:99-104.
[PubMed]
137.
Johnson JL, Ssekasanvu E, Okwera A, Mayanja H, Hirsch CS, Nakibali JG, Jankus DD, Eisenach KD, Boom WH, Ellner JJ, Mugerwa RD; Uganda-Case Western Reserve University Research Collaboration: Randomized trial of adjunctive interleukin-2 in adults with pulmonary tuberculosis. Am J Respir Crit Care Med 2003;168:185-191.
[PubMed]
© 2016 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2016
You do not currently have access to this content.
